Clinical Trial Update: Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sorafenib as salvage therapy for relapsed or refractory acute myeloid leukemia with FLT3-ITD mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: The University of Hong Kong | Conditions: FLT3-ITD Mutation, AML | Phase 2 | Status: COMPLETED